Collectively, these results demonstrate that losartan has a profound effect on the ECM and the tumor stroma, effects which are consistent with the inhibition of TGF-β signaling and that are likely to contribute to enhancement of tumor invasion by CD8+ Teff cells. This evidence concerns the gene TGFB1 and neoplasm.